More Than 200 Biotech Companies Slated to Present At the BIO CEO & Investor Conference

  • Contact: Erin Reese
    202-962-9200
  • Recommend
  • Tweet
  • Print
  • Email

WASHINGTON, D.C. (February 19, 2004) - Executives representing more than 400 biotechnology and pharmaceutical companies from around the world will gather Feb. 23 - 25 at the Waldorf=Astoria Hotel in New York to network with the financial and venture capital communities.

The occasion is the BIO CEO & Investor Conference, the largest biotechnology industry-run investor event in the world. Details are posted at www.bio.org/ceo.

More than 200 attending companies will give presentations, either in a standard corporate presentation or by participating in one of the 30 new Focus Session panels that bring together industry and clinical experts to discuss major therapeutic and business strategy topics.

Companies featured at this year's event include:

Abgenix, Inc., Acambis plc, Actelion Pharmaceuticals Ltd., Acuity Pharmaceuticals, Inc., Acusphere, Inc., Aderis Pharmaceuticals, Inc., Adolor Corporation, Aegera Therapeutics Inc., AEterna Laboratories Inc., AGY Therapeutics, Inc., Albany Molecular Research, Inc., Alkermes, Inc., Allon Therapeutics, Inc., Allos Therapeutics, Alteon Inc., AnGes MG, Inc., Angiogenix, Inc., AnorMED Inc., Antigenics Inc., Antisoma plc, Arcturus Bioscience, Inc., Ardana Bioscience Limited, Arena Pharmaceuticals, Inc., Array BioPharma Inc., AtheroGenics, Inc., Auxilium Pharmaceuticals, Inc., Avalon Pharmaceuticals, Inc., AVANT Immunotherapeutics, Inc., Axonyx Inc., BioCryst Pharmaceuticals, Inc., Bionaut Pharmaceuticals, Inc., Biovitrum AB, CancerVax Corporation, Caprion Pharmaceuticals Inc., CEL-SCI Corporation, Celera Genomics Group, CellGate Inc., Cell Genesys, Inc., Cell Therapeutics, Inc, Celgene Corporation, ChemoCentryx, Inc., Coley Pharmaceutical Group, Inc., CombinatoRx, Incorporated, CombiMatrix Corporation, Compugen Ltd., Concurrent Pharmaceuticals, Inc., Connetics Corporation, Corautus Genetics Inc., Cubist Pharmaceuticals, Inc., CuraGen Corporation, Cyclacel Limited, Cypress Bioscience, Inc., Cytogen Corporation, CytRx Corporation, deCODE genetics, Inc., Dendreon Corporation, Depomed, Inc., Descartes Therapeutics, Inc., Discovery Laboratories, Inc., Diversa Corporation, DOV Pharmaceutical, Inc., Dyax Corp., Dynogen Pharmaceuticals, Inc., Elixir Pharmaceuticals, Inc., EluSys Therapeutics, Inc., Emisphere Technologies, Inc., Encysive Pharmaceuticals Inc., EntreMed, Inc., Enzon, Inc., EpiCept Corp., Epigenomics AG, Evotec OAI AG, Exelixis, Inc., Flamel Technologies S.A., Gemin X Biotechnologies Inc., Genaera Corporation, Genaissance Pharmaceuticals, Inc., Genelabs Technologies, Inc., Genencor International, Inc., Generex Biotechnology Corporation, Genome Therapeutics Corporation, Genta Incorporated, GenVec, Inc., Geron Corporation, Gilead Sciences, Inc., GPC Biotech AG, GTC Biotherapeutics, Inc., Guilford Pharmaceuticals Inc., Hollis-Eden Pharmaceuticals, Inc., Human Genome Sciences, Inc., Hybridon, Inc., Hybrigenics SA, Hydra Biosciences, Inc., Icagen, Inc., Idun Pharmaceuticals, Inc., ImClone Systems Incorporated, ImmunoGen, Inc., Ingenium Pharmaceuticals AG, Insmed Incorporated, InterMune, Inc., Intradigm Corporation, Introgen Therapeutics, Inc., Isis Pharmaceuticals, Inc., Keryx Biopharmaceuticals, Inc., La Jolla Pharmaceutical Company, Lexicon Genetics Incorporated, Ligand Pharmaceuticals Incorporated, MacroChem Corporation, Maxim Pharmaceuticals Inc., Maxygen, Inc., Medarex, Inc., MediGene AG, Merrimack Pharmaceuticals, Inc., Metabolex, Inc., Metaphore Pharmaceuticals, Inc., MGI Pharma, Inc., Nabi Biopharmaceuticals, Nastech Pharmaceutical Company Inc., Nektar Therapeutics, Neose Technologies, Inc., NeoRx Corporation, Neurogen Corporation, Newron Pharmaceuticals SpA, NexMed, Inc., Nektar Therapeutics, NitroMed, Inc., Nobex Corporation, Novavax, Inc., NPS Pharmaceuticals, Inc., Nucleonics Inc., Nuvelo, Inc., Onyx Pharmaceuticals, Inc., Paradigm Genetics, Inc., Perlegen Sciences, Inc., Pharmos Corporation, Praecis Pharmaceuticals Incorporated, Protein Design Labs, Inc., PTC Therapeutics, Inc., QLT Inc., Quorex Pharmaceuticals, Inc., Raven biotechnologies, inc., Regeneron Pharmaceuticals, Inc., Repligen Corporation, Rigel Pharmaceuticals, Inc., Salmedix, Inc., Sangamo BioSciences, Inc., Scion Pharmaceuticals, Inc., Seattle Genetics, Inc., Sirna Therapeutics, Inc., Spectrum Pharmaceuticals, Inc., StemCells, Inc., Structural GenomiX, Inc., Sunesis Pharmaceuticals, Inc., Synta Pharmaceuticals Corp., Tanox, Inc., Targeted Genetics Corporation, Telik, Inc., Therion Biologics Corporation, TransForm Pharmaceuticals, Inc., Transkaryotic Therapies, Inc., U.S. Genomics, Inc., Valentis, Inc., VaxGen Inc., Vertex Pharmaceuticals Incorporated, Vical Incorporated, Vicuron Pharmaceuticals Inc., XTL Biopharmaceuticals Ltd., ZymoGenetics, Inc.

Companies participating in the BIO CEO International Networking Reception include:

Apovia AG, Applied Biosystems Group, APT Therapeutics, Inc., ARIUS Research Inc., AviGenics, Inc., BIOBASE GmbH, BioSante Pharmaceuticals, Inc., BioStratum Incorporated, Borean Pharma A/S, Cetek Corporation, Corautus Genetics Inc., Cytovax Biotechnologies Inc., DarPharma, Inc., Diffusion Pharmaceuticals LLC, Gamida-Cell Ltd., Genmab A/S, Genteric, Inc., GlycoGenesys, Inc., Ipsat Therapies Ltd, Juvaris BioTherapeutics, Inc., Lorantis Ltd., Medicure Inc., Medisyn Technologies, Inc., Metaphore Pharmaceuticals, Inc., NaPro BioTherapeutics, Inc., NeoRx Corporation, Oncolytics Biotech Inc., Panacos Pharmaceuticals Inc., Patheon Inc., Pro-Pharmaceuticals, Inc., Protein Sciences Corporation, Protez Pharmaceuticals Inc., Provid Pharmaceuticals Inc., Selective Genetics, Inc., StemCells, Inc., Target Discovery, Inc., Transave, Inc., TransForm Pharmaceuticals, Inc., TranXenoGen, Inc., U.S. Genomics Inc., VasoGenix Pharmaceuticals, Inc., Velcura Therapeutics, Inc., Xencor, Inc., YM BioSciences Inc., and Zelos Therapeutics Inc.

Registration is complimentary for credentialed news media and investors. Online registration has expired for media. On-site registration will be open only to reporters and editors working full-time for print or broadcast news organizations with valid media credentials.

BIO represents more than 1,000 biotechnology companies, academic institutions, state biotechnology centers and related organizations in all 50 U.S. states and 33 other nations. BIO members are involved in the research and development of health-care, agricultural, industrial and environmental biotechnology products.

###


About BIO
BIO is the world's largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world. BIOtechNOW is BIO's blog chronicling “innovations transforming our world” and the BIO Newsletter is the organization’s bi-weekly email newsletter. Subscribe to the BIO Newsletter.